- Home
- KROS vs SABR Comparison
KROS vs SABR Comparison
Compare KROS & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | SABR |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 652.0M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KROS | SABR |
|---|---|---|
| Price | $10.93 | $1.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $22.25 | $3.70 |
| AVG Volume (30 Days) | 376.7K | ★ 17.7M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 146.00 | ★ 283.56 |
| EPS | ★ 2.30 | 1.34 |
| Revenue | $243,864,000.00 | ★ $3,866,956,000.00 |
| Revenue This Year | N/A | $7.40 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | $4.78 | ★ $1.28 |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $9.12 | $0.81 |
| 52 Week High | $22.55 | $3.63 |
Technical Indicators
Market Signals| Indicator | KROS | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 17.12 | 56.52 |
| Support Level | N/A | $1.20 |
| Resistance Level | $15.21 | $1.70 |
| Average True Range (ATR) | 0.71 | 0.20 |
| MACD | -0.22 | 0.04 |
| Stochastic Oscillator | 7.37 | 65.13 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.